The GAA has confirmed that a sample recently provided by one of its players as part of the Irish Sports Council’s Anti-Doping Programme has revealed an adverse analytical finding regarding the use of Salbutamol. The finding will require the player to show that the result was the consequence of the therapeutic use of inhaled Salbutamol.
Salbutamol is a commonly prescribed treatment for asthma, but it is a banned substance, and players are only allowed to take the drug under strictly controlled guidelines. The player involved has not been named, but Kerry chairman Jerome Conway has said that it is a Kerry player, and that the test took place after a Championship match this year. In accordance with the provisions of the Irish Anti-Doping Rules, the GAA are obliged to provisionally suspend the player involved pending the outcome of a hearing of the Anti-Doping Hearings Committee.
A date for this meeting has not yet been scheduled.